Journal Scans
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Everolimus Improved PFS in Advanced Neuroendrocrine Pancreatic Cancer
JC Yao, MH Shah, T Ito, CL Bohas, EM Wolin, E Van Cutsem, TJ Hobday, T Okusaka, J Capdevila, EGE de Vries, P Tomassetti, ME Pavel, S Hoosen, T Haas, J Lincy, D Lebwohl, K Öberg
Yes
20110110
2011 Feb 10
N Engl J Med
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
N Engl J Med. 2011 Feb 10;364514-523, JC Yao, MH Shah, T Ito, CL Bohas, EM Wolin, E Van Cutsem, TJ Hobday, T Okusaka, J Capdevila, EGE de Vries, P Tomassetti, ME Pavel, S Hoosen, T Haas, J Lincy, D Lebwohl, K Öberg
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), which is a serine–threonine kinase that stimulates cell growth, proliferation, and angiogenesis. Activation of mTOR via insulin-like growth factor 1 is associated with proliferation of pancreatic neuroendocrine tumor cells. This randomized, placebo-controlled, double-blind, phase III study sponsored by Novartis, the RAD001 in Advanced Neuroendocrine Tumors (RADIANT-3) study, evaluated the effects of everolimus on survival in patients...
